
An ESMO study reveals that poor quality of real-world data from oncology studies is still an issue
Scarcity of prospective data was reported as well as a limited use of real-world evidence as definitive evidence to regulatory approval decisions of targeted therapies in Europe

Adoptive cell therapy using TILs shows clinically meaningful and durable efficacy in advanced mucosal melanoma
Antitumour responses were consistent with those previously reported for a broader population of patients with advanced melanoma

PROs support dostarlimab plus chemotherapy as a new standard of care in endometrial cancer
Data from selected patients in the RUBY trial show improvements in QoL domains over the course of treatment and benefits compared with placebo

How can we overcome resistance to immune checkpoint inhibitors in NSCLC?
Results from studies presented at the ESMO Congress 2023 (Madrid, 20–24 October) outline different strategies involving indirect immune modulation and direct enhanced tumour cytotoxicity to improve on chemotherapy as the current standard of second-line care after ICI progression

Checkpoint inhibition improves outcomes in high-risk, locally advanced cervical cancer
In the KEYNOTE-A18 study, the combination of pembrolizumab and concurrent chemoradiotherapy significantly improved progression-free survival

Longer PFS reported with a quadruple treatment regimen in EGFR- or ALK-mutated NSCLC
Promising data from the ATTLAS phase III study indicate a potential new approach for treating patients progressing on TKIs

Phase III data confirm that adjuvant radiotherapy has no benefit following radical prostatectomy
Final results from the RADICALS-RT trial show that observation with salvage RT for prostate-specific antigen failure should be the current standard strategy after surgery

Sitravatinib plus nivolumab does not improve survival in NSCLC after immunotherapy and chemotherapy
The SAPPHIRE trial failed to meet its primary endpoint compared with chemotherapy

First-line pembrolizumab combination significantly improves PFS in HER2-positive metastatic G/GEJ adenocarcinoma
Adding immunotherapy to standard of care shows benefit compared with placebo and is confirmed to be practice-changing for this patient population

Data are still insufficient to recommend immune checkpoint inhibitors in perioperative therapy for gastric/gastro-oesophageal junction cancers
The impact of immunotherapy on disease progression and survival remains uncertain, but biomarker selection may be the future